StockNews.AI
TLPH
StockNews.AI
146 days

Talphera to Host Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update Call and Webcast on Monday, March 31, 2025

1. Talphera, Inc. will release Q4 and FY 2024 financial results on March 31, 2025. 2. A live webcast and call will follow to discuss results and business updates. 3. Talphera's lead product, Niyad™, is a promising anticoagulant with FDA Breakthrough status. 4. The webcast will be available for replay on the Talphera website for 90 days.

4m saved
Insight
Article

FAQ

Why Bullish?

The scheduled financial results and product updates may attract investor interest. Historical examples show that positive updates typically boost stock prices.

How important is it?

Financial disclosures and product advancements are critical for projecting future performance. Positive results can lead to increased investor confidence and higher stock valuations.

Why Long Term?

As Talphera progresses with its lead product and receives regulatory recognition, the long-term potential increases. Previous FDA designations often correlate with sustained stock performance improvements.

Related Companies

TLPH
, /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release fourth quarter and full-year 2024 financial results after market close on Monday, March 31, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Standard to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section. The webcast will include a slide presentation and a replay will be available on the Talphera website for 90 days following the event. Conference Call Information Investors who wish to participate in the conference call may do so by dialing 1-800-836-8184 for North American callers, or 1-646-357-8785 (toll applies) for international callers outside of Canada. The conference ID is 11814. About Talphera, Inc. Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™ is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA). This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com. SOURCE Talphera, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News